




Recovering Hearts. Saving Lives.™

Q3 FY 2017 Earnings Call


Financial Results & Operational Highlights

FINANCIAL RESULTS, Q3 FY 2017


Revenue (\$M) & Growth Rate




Cash (\$M)



Gross Margin %




Operating Margin %




U.S. UTILIZATION MIX, Q3 FY 2017

Revenue by Impella Device




Utilization by Indication*



Abiomed Revenue Growth:
34%

U.S. Patient Growth:
32%

Hospital Site Penetration



* Protected PCI patients are elective and urgent PCI patients. Emergent includes AMI cardiogenic shock, post-surgery shock and other shock.

ABIOMED FY 2017 GUIDANCE, AS OF JANUARY 26, 2017

Abiomed FY'17 Post-Q3 Guidance

Updated Revenue*
\$440 - 445 ; 34 – 35%

Operating Margin %
18 – 20%

The Company is raising the lower end of the revenue range to \$440 million and projects Q4 FY'17 revenue to be around \$122 million

* Initial revenue guidance for FY17 was \$430 - \$445 ; 30 – 35% growth y-o-y